Tags

Type your tag names separated by a space and hit enter

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
J Bone Miner Metab. 2011 May; 29(3):328-33.JB

Abstract

The aim of this study was to assess the efficacy and safety of a once-yearly zoledronic acid treatment for Chinese women with postmenopausal osteoporosis in Taiwan and Hong Kong. This post hoc subpopulation analysis, from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly Pivotal Fracture Trial, enrolled 323 Chinese women with osteoporosis who were randomly given either annual infusions of zoledronic acid or placebo for 3 consecutive years. The incidence of fractures and changes in bone mineral density (BMD) were measured; adverse events (AEs) and tolerability were recorded and assessed. The results of this study at 36 months demonstrate that there was a significantly reduced risk of morphometric vertebral fracture and clinical vertebral fracture in subjects treated with zoledronic acid (P < 0.05). In addition, there were significant increases of BMD by 4.9%, 4.3%, and 7.0% in the total hip, femoral neck, and trochanter, respectively, in the zoledronic acid group compared with the placebo group (P < 0.001 for all comparisons). The incidences of AEs were comparable between the two groups. Thus, once-yearly zoledronic acid treatment showed bone protection effects by reducing the risk of vertebral fracture and increasing BMD in Chinese women with postmenopausal osteoporosis.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Kaohsiung, Taiwan, ROC.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20922438

Citation

Hwang, Jawl-Shan, et al. "The Effects of Intravenous Zoledronic Acid in Chinese Women With Postmenopausal Osteoporosis." Journal of Bone and Mineral Metabolism, vol. 29, no. 3, 2011, pp. 328-33.
Hwang JS, Chin LS, Chen JF, et al. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab. 2011;29(3):328-33.
Hwang, J. S., Chin, L. S., Chen, J. F., Yang, T. S., Chen, P. Q., Tsai, K. S., & Leung, P. C. (2011). The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism, 29(3), 328-33. https://doi.org/10.1007/s00774-010-0223-y
Hwang JS, et al. The Effects of Intravenous Zoledronic Acid in Chinese Women With Postmenopausal Osteoporosis. J Bone Miner Metab. 2011;29(3):328-33. PubMed PMID: 20922438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. AU - Hwang,Jawl-Shan, AU - Chin,Lin-Show, AU - Chen,Jung-Fu, AU - Yang,Tzay-Shing, AU - Chen,Po-Quang, AU - Tsai,Keh-Sung, AU - Leung,Ping Chung, Y1 - 2010/10/05/ PY - 2010/05/01/received PY - 2010/08/25/accepted PY - 2010/10/6/entrez PY - 2010/10/6/pubmed PY - 2011/9/7/medline SP - 328 EP - 33 JF - Journal of bone and mineral metabolism JO - J Bone Miner Metab VL - 29 IS - 3 N2 - The aim of this study was to assess the efficacy and safety of a once-yearly zoledronic acid treatment for Chinese women with postmenopausal osteoporosis in Taiwan and Hong Kong. This post hoc subpopulation analysis, from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly Pivotal Fracture Trial, enrolled 323 Chinese women with osteoporosis who were randomly given either annual infusions of zoledronic acid or placebo for 3 consecutive years. The incidence of fractures and changes in bone mineral density (BMD) were measured; adverse events (AEs) and tolerability were recorded and assessed. The results of this study at 36 months demonstrate that there was a significantly reduced risk of morphometric vertebral fracture and clinical vertebral fracture in subjects treated with zoledronic acid (P < 0.05). In addition, there were significant increases of BMD by 4.9%, 4.3%, and 7.0% in the total hip, femoral neck, and trochanter, respectively, in the zoledronic acid group compared with the placebo group (P < 0.001 for all comparisons). The incidences of AEs were comparable between the two groups. Thus, once-yearly zoledronic acid treatment showed bone protection effects by reducing the risk of vertebral fracture and increasing BMD in Chinese women with postmenopausal osteoporosis. SN - 1435-5604 UR - https://www.unboundmedicine.com/medline/citation/20922438/The_effects_of_intravenous_zoledronic_acid_in_Chinese_women_with_postmenopausal_osteoporosis_ L2 - https://dx.doi.org/10.1007/s00774-010-0223-y DB - PRIME DP - Unbound Medicine ER -